Connect with us


CDC advisers will meet Thursday to discuss the need to strengthen coronavirus and J&J vaccine safety



The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet from 11 a.m. to 4:30 p.m. ET. The court is not expected to vote on issues on the agenda.

ACIP is a group of external medical experts in the fields of vaccinology, immunology, pediatrics, internal medicine, nursing, virology, public health, infectious diseases and other subspecialties. The CDC typically accepts your recommendations once the votes are cast.

ACIP has provided crucial guidance for the entire pandemic, including advice on emergency use authorization for the three Covid-19 vaccines currently available in the US Pfizer vaccine for children aged 12 to 15 years and in april to end the J&J vaccine break due to a rare blood clotting disorder that has occurred in a small number of vaccine receptors.
On Thursday, ACIP will address several new issues on the safety and durability of Covid-19 vaccines. To begin, ACIP will review recent data on cases of Guillain-Barré syndrome (GBS) among people vaccinated against Covid-19 with the J&J coronavirus vaccine. Federal health officials say there have been about 100 preliminary reports on cases of GBS, a rare neurological disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes temporary paralysis, among the nearly 13 million people who have received the vaccine.
The United States Food and Drug Administration last week it already updated the J&J vaccine label to include GBS as a rare risk. ACIP’s debate tomorrow will focus on the question of whether, given this adverse fact, the benefit of the J&J vaccine still outweighs the risk of GBS. ACIP is expected to say yes.

Tomorrow’s meeting was precipitated by this recently identified adverse event, Dr. William Schaffner, a professor in the Infectious Diseases Division at Vanderbilt University Medical Center and a member of the ACIP, told CNN. “There will be no formal votes and it will be concluded that the risk of Covid is very high and the risks of the vaccine very low. Real, but very low,” he added.

ACIP will also address the issue of coronavirus vaccine enhancers, with priority given to reviewing data on the need for booster vaccines for immunocompromised individuals. Recent reports have suggested that Covid-19 vaccines are not effective enough in people with a weakened immune system and last week the CDC revised its guidelines for fully vaccinated people. That warned immunocompromised people that vaccines may not be as effective for them, and they are encouraged to continue with safety precautions as if they were not vaccinated. However, the CDC has not yet formally recommended reinforcements for anyone.

The goal of ACIP tomorrow is to analyze the need for reinforcements and review what data is currently available and published. “What [ACIP] it will prove tomorrow that evidence is very scarce, ”Schaffner says, which means, ultimately, that the group will not vote for the proponents.

Earlier this month, Pfizer announced it would seek permission to provide a third dose of the Covid-19 vaccine as a booster, citing data from Israel on the continued spread of the coronavirus and limited efficacy against the Delta variant. more transmissible.

Health officials, including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, continue to say the U.S. needs more data before recommending anyone an increase in the coronavirus vaccine.

“The CDC and the FDA said that according to the data we know right now, we don’t need a boost,” Fauci told CNN’s Chris Cuomo last week. “That doesn’t mean that won’t change. In fact, we may actually need to give impetus at some point, either in a general way or to certain select groups, such as the elderly or those with underlying conditions.”



Amazon Discloser Is A Participant In The Amazon Services Llc Associates Program, An Affiliate Advertising Program Designed To Provide A Means For Sites To Earn Advertising Fees By Advertising And Linking To Amazon, The Amazon Logo, Amazonsupply, And The Amazonsupply Logo Are Trademarks Of, Inc. Or Its Affiliates. As An Amazon Associate, We Earn Affiliate Commissions From Qualifying Purchases.